AccuStem Sciences Limited (ACMSY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AccuStem Sciences Limited (ACMSY) trades at $0.13 with AI Score 44/100 (Grade C). AccuStem Sciences Limited, incorporated in 2020 and based in London, UK, specializes in genomic signature-based assays for breast cancer prognosis. Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ACMSY: ACMSY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACMSY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACMSY: the 1 perspectives are evenly split.
How is this calculated? →AccuStem Sciences Limited (ACMSY) Healthcare & Pipeline Overview
AccuStem Sciences Limited, based in London, UK, specializes in developing genomic signature-based assays. The company's core focus is on prognosticating early and late recurrence risks for ER+/HER2 breast cancer in early-stage patients, positioning it within the specialized medical diagnostics and research sector.
What Is the Investment Thesis for ACMSY?
AccuStem Sciences Limited presents an investment thesis centered on its specialized focus within the high-growth genomic diagnostics market, particularly for breast cancer prognosis. The company's core value driver is its development of genomic signature-based assays designed to predict early and late recurrence in ER+/HER2 breast cancer patients. This specialization addresses a significant unmet need in personalized oncology, offering the potential for improved patient outcomes and more tailored treatment plans. Key growth catalysts include the potential for regulatory approvals of its assays, successful clinical validation, and subsequent market adoption by oncologists and healthcare systems. The broader biotechnology industry's growth trend, driven by advancements in genomics and personalized medicine, provides a favorable backdrop for AccuStem's specialized offerings. However, the company's listing on the OTC Other tier introduces significant risk factors, including limited transparency, potential liquidity challenges, and a higher barrier to market acceptance compared to exchange-listed peers. Future progress in assay commercialization and strategic partnerships will be critical for realizing its growth potential.
Based on FMP financials and quantitative analysis
ACMSY Key Highlights
- AccuStem Sciences Limited was incorporated in 2020, indicating a relatively young company in the medical diagnostics sector.
- The company specializes in genomic signature-based assays, focusing on the prognosis of breast cancer recurrence.
- Its diagnostic efforts are specifically targeted at ER+/HER2 breast cancer in early-stage patients, addressing a defined medical need.
- AccuStem Sciences operates within the Medical - Diagnostics & Research industry, a segment characterized by innovation and regulatory rigor.
- The company's stock trades on the OTC market, classified under the OTC Other tier, which implies specific considerations for investors.
Who Are ACMSY's Competitors?
ACMSY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACMSY's Key Strengths?
- Specialized focus on genomic signature-based assays for ER+/HER2 breast cancer prognosis.
- Operates in the high-growth sector of personalized medicine and oncology diagnostics.
- Potential for significant impact on patient management and treatment decisions.
- Relatively young company, potentially agile in adapting to new scientific advancements.
What Are ACMSY's Weaknesses?
- Limited public information available due to OTC Other listing and young company status.
- No dividend yield, which may deter income-focused investors.
- High regulatory hurdles inherent in the medical diagnostics industry.
- Potential for limited liquidity and transparency as an OTC-listed entity.
What Could Drive ACMSY Stock Higher?
- Potential regulatory approvals for AccuStem's genomic signature-based assays, which would enable commercialization and market entry.
- Publication of positive clinical trial data or validation studies demonstrating the efficacy and utility of their breast cancer prognostic assays.
- Formation of strategic partnerships with larger diagnostic companies or pharmaceutical firms to aid in commercialization, distribution, or co-development.
- Continued research and development efforts leading to the expansion of their assay pipeline into new cancer indications or improved diagnostic capabilities.
What Are the Key Risks for ACMSY?
- Significant regulatory hurdles and lengthy approval processes inherent in the medical diagnostics industry, which could delay market entry for their assays.
- Intense competition from established diagnostic companies and other biotechnology firms developing similar or alternative prognostic tools for breast cancer.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts, particularly as an OTC-listed company.
- Limited public information and transparency due to its OTC Other tier listing, which can deter institutional investors and impact investor confidence.
- Market acceptance and adoption rate of AccuStem's novel genomic assays by healthcare providers and patients, even after regulatory approval.
What Are the Growth Opportunities for ACMSY?
- Expansion of Genomic Assay Adoption: The global market for precision oncology and genomic testing is experiencing robust growth, driven by increasing understanding of cancer biology and demand for personalized treatments. AccuStem's specialized genomic assays for ER+/HER2 breast cancer recurrence could see significant uptake as healthcare systems increasingly integrate such tools into standard care. The market for breast cancer diagnostics alone is projected to reach several billion dollars by the late 2020s, providing a substantial addressable market for AccuStem's offerings, contingent on strong clinical evidence and regulatory approvals.
- Development of New Diagnostic Panels: Leveraging its core expertise in genomic signature identification, AccuStem has the opportunity to expand its product pipeline beyond ER+/HER2 breast cancer. This could involve developing prognostic or predictive assays for other cancer types, different stages of breast cancer, or even companion diagnostics for novel therapeutic agents. This diversification would broaden its market reach and reduce reliance on a single product, tapping into the wider oncology diagnostics market which is continuously seeking innovative solutions for various cancer indications.
- Geographic Market Expansion: Currently based in London, UK, AccuStem has the potential to expand its market presence beyond its home country. Successful regulatory approvals in major markets like the European Union, North America (FDA approval), and key Asian countries would significantly increase its addressable patient population and revenue potential. Establishing distribution networks or forming strategic partnerships with larger diagnostic companies or pharmaceutical firms could facilitate this expansion, allowing its assays to reach a global patient base over the next 3-5 years.
- Strategic Partnerships and Collaborations: Forming alliances with pharmaceutical companies, academic research institutions, or large diagnostic laboratory networks represents a significant growth opportunity. Such partnerships could provide AccuStem with access to broader research capabilities, clinical trial networks, and established commercialization channels. Collaborations could also lead to the development of companion diagnostics, linking AccuStem's assays directly to specific drug therapies, thereby enhancing their market value and accelerating adoption within the next 2-4 years.
- Advancements in Breast Cancer Research and Treatment: The ongoing evolution in breast cancer research, including the discovery of new biomarkers and therapeutic targets, continuously creates opportunities for innovative diagnostic tools. AccuStem's ability to adapt and develop new genomic signatures that align with the latest scientific breakthroughs could ensure its long-term relevance and growth. Staying at the forefront of research and integrating new knowledge into its assay development pipeline will be crucial for capturing emerging market segments and maintaining a competitive edge in the rapidly advancing field of oncology diagnostics.
What Opportunities Does ACMSY Have?
- Growing demand for personalized medicine and precision oncology globally.
- Expansion into new diagnostic panels for other cancer types or stages.
- Formation of strategic partnerships for commercialization and research.
- Geographic expansion into major healthcare markets beyond the UK.
What Threats Does ACMSY Face?
- Intense competition from established diagnostic companies and larger biotech firms.
- Challenges in securing necessary regulatory approvals for its assays.
- Potential for funding difficulties typical of early-stage, OTC-listed biotech companies.
- Rapid technological advancements by competitors could render current assays less competitive.
What Are ACMSY's Competitive Advantages?
- Proprietary genomic signatures and assay technology for breast cancer recurrence prognosis.
- Specialized focus on ER+/HER2 breast cancer, creating a niche market expertise.
- Scientific expertise in genomics and oncology, essential for assay development and validation.
- Potential for regulatory approvals (once obtained) for its specific diagnostic tests, creating market entry barriers for competitors.
What Does ACMSY Do?
AccuStem Sciences Limited is a UK-based biotechnology company incorporated in 2020, with its headquarters located in London. The company operates within the highly specialized Medical - Diagnostics & Research industry, focusing on advancing precision medicine through genomic technologies. Its primary business revolves around the development and commercialization of genomic signature-based assays. These advanced diagnostic tools are specifically designed for the prognosis of early and late recurrence of ER+/HER2 breast cancer in patients diagnosed with early-stage disease. This niche focus addresses a critical need in oncology, providing clinicians with more precise information to guide treatment decisions and patient management strategies. While the company is relatively young, its dedication to genomic assays for a specific breast cancer subtype positions it within the growing field of personalized diagnostics. Information on its specific market position and key product lines beyond its core assay business is limited, as noted by existing AI insights. However, its operation within the broader biotechnology sector suggests a potential for developing and commercializing novel therapeutic products in addition to its diagnostic focus. As an OTC-listed company, AccuStem Sciences Limited operates with a higher risk profile, necessitating close monitoring of its product development, regulatory progress, and financial disclosures.
What Products and Services Does ACMSY Offer?
- Develops genomic signature-based assays for medical diagnostics.
- Focuses on the prognosis of breast cancer, specifically recurrence risk.
- Identifies the risk of early recurrence in early-stage breast cancer patients.
- Identifies the risk of late recurrence in early-stage breast cancer patients.
- Targets ER+/HER2 breast cancer, a specific subtype of the disease.
- Operates within the Medical - Diagnostics & Research sector.
- Aims to provide tools for personalized medicine in oncology.
- Based in London, United Kingdom, and incorporated in 2020.
How Does ACMSY Make Money?
- Develops and commercializes proprietary genomic signature-based assays for breast cancer prognosis.
- Generates revenue through the sale or licensing of its diagnostic tests to healthcare providers, hospitals, or specialized laboratories.
- Focuses on a niche market within oncology diagnostics, providing specialized tools for personalized patient management.
- Potentially seeks partnerships for broader distribution and market penetration of its diagnostic products.
What Industry Does ACMSY Operate In?
AccuStem Sciences Limited operates within the dynamic and rapidly evolving Medical - Diagnostics & Research industry, specifically targeting the oncology segment with its genomic signature-based assays. This industry is characterized by continuous innovation, driven by advancements in molecular biology, genomics, and personalized medicine. The market for cancer diagnostics, particularly those offering prognostic information, is experiencing significant growth due to an increasing incidence of cancer, greater emphasis on early detection, and the demand for tailored treatment strategies. AccuStem's focus on ER+/HER2 breast cancer positions it in a competitive landscape alongside established diagnostic companies and other biotech firms developing precision oncology tools. While the overall biotechnology industry offers substantial growth potential, AccuStem's success will depend on the clinical validation, regulatory approval, and market adoption of its specialized assays, differentiating itself through the accuracy and utility of its genomic signatures.
Who Are ACMSY's Key Customers?
- Oncologists and breast cancer specialists who require advanced prognostic tools.
- Hospitals and cancer treatment centers seeking to improve patient risk stratification and treatment planning.
- Pathology laboratories and diagnostic service providers integrating genomic testing into their offerings.
- Potentially pharmaceutical companies for companion diagnostic development in future therapeutic pipelines.
How AccuStem Sciences Limited Is Valued
Relative to its peer group, ACMSY's quantitative score of 44/100 is below the peer average of 64/100.
Company Profile
AccuStem Sciences Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in London, GB. ACMSY has traded publicly since 2021.
ROE 206%Key Financial Metrics
Return on equity for AccuStem Sciences Limited stands at 205.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
ACMSY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on genomic signature-based assays for ER+/HER2 breast cancer prognosis.
- Operates in the high-growth sector of personalized medicine and oncology diagnostics.
- Potential for significant impact on patient management and treatment decisions.
- Relatively young company, potentially agile in adapting to new scientific advancements.
Bear Case
- Limited public information available due to OTC Other listing and young company status.
- No dividend yield, which may deter income-focused investors.
- High regulatory hurdles inherent in the medical diagnostics industry.
- Potential for limited liquidity and transparency as an OTC-listed entity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ACMSY Latest News
No recent news available for ACMSY.
ACMSY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACMSY.
Price Targets
Wall Street price target analysis for ACMSY.
ACMSY MoonshotScore
What does this score mean?
The MoonshotScore rates ACMSY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ACMSY OTC Market Information
AccuStem Sciences Limited is listed on the OTC Other tier, which represents companies that do not meet the minimum financial or disclosure requirements for OTCQX or OTCQB markets. Unlike major exchanges such as NYSE or NASDAQ, which have stringent listing standards for financial performance, corporate governance, and public disclosure, the OTC Other tier has minimal requirements. This classification often includes companies with limited public information, distressed financials, or those that are very early-stage. Investors typically face higher risks due to less transparency and potentially less reliable financial reporting compared to companies on higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and financial transparency due to minimal disclosure requirements.
- Lower liquidity, leading to wider bid-ask spreads and difficulty in executing trades.
- Increased susceptibility to market manipulation and fraudulent activities.
- Higher volatility and greater price fluctuations compared to exchange-listed stocks.
- Difficulty in obtaining reliable valuation metrics and analyst coverage.
- Verify the company's current financial statements and any available disclosures directly from the company or OTC Markets Group.
- Research any news, press releases, or corporate actions announced by the company.
- Assess the company's business model, product development stage, and market potential thoroughly.
- Investigate the management team's background, experience, and track record.
- Understand the regulatory landscape for their specific products and the status of any approvals.
- Evaluate the company's funding status and potential need for future capital raises.
- Consider the potential for delisting or further restrictions on trading.
- The company's incorporation in 2020 in London, UK, provides a verifiable legal entity.
- Its stated business focus on genomic signature-based assays for breast cancer prognosis indicates a specific scientific endeavor.
- Operating within the Medical - Diagnostics & Research sector, which is a legitimate and regulated industry.
- The explicit mention of ER+/HER2 breast cancer indicates a targeted and specific area of medical research.
AccuStem Sciences Limited Healthcare Stock: Key Questions Answered
What is AccuStem Sciences Limited's core business and market focus?
AccuStem Sciences Limited's core business is the development and commercialization of genomic signature-based assays. These specialized diagnostic tools are designed to provide prognostic information regarding the early and late recurrence of ER+/HER2 breast cancer in patients diagnosed with early-stage disease. The company's market focus is within the precision oncology segment of the Medical - Diagnostics & Research industry, aiming to equip oncologists with advanced insights to personalize treatment strategies and improve patient outcomes. By targeting a specific breast cancer subtype, AccuStem seeks to address a defined clinical need with highly specialized genomic solutions.
How does AccuStem Sciences Limited navigate regulatory approval processes for its genomic assays?
AccuStem Sciences Limited operates within a highly regulated environment, and navigating the regulatory approval processes is critical for the commercialization of its genomic assays. While specific details on their regulatory track record or pending approvals are not publicly disclosed, the company would typically need to adhere to stringent guidelines set by regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA) in Europe, or the Food and Drug Administration (FDA) in the United States for broader market access. This involves extensive pre-clinical and clinical validation studies to demonstrate the safety, accuracy, and clinical utility of their assays, followed by comprehensive submissions and ongoing compliance with quality management systems.
What are the implications of AccuStem Sciences Limited's OTC Other listing for investors?
AccuStem Sciences Limited's listing on the OTC Other tier carries several implications for investors. This tier typically includes companies with limited public disclosure, which can result in a lack of comprehensive financial and operational information. Investors may face challenges in conducting thorough due diligence due to reduced transparency. Furthermore, OTC Other stocks often experience lower trading volumes and wider bid-ask spreads, leading to reduced liquidity. This can make it difficult to buy or sell shares efficiently and may contribute to higher price volatility. The OTC Other classification also signals a higher risk profile compared to companies listed on major exchanges or even higher OTC tiers, necessitating careful consideration and extensive research by potential investors.
What are the key factors to evaluate for ACMSY?
AccuStem Sciences Limited (ACMSY) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ACMSY data refresh on this page?
ACMSY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACMSY's recent stock price performance?
AccuStem Sciences Limited (ACMSY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on genomic signature-based assays for ER+/HER2 breast cancer prognosis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACMSY overvalued or undervalued right now?
Valuing AccuStem Sciences Limited (ACMSY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACMSY?
Before investing in AccuStem Sciences Limited (ACMSY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC Other listing and relatively recent incorporation.
- Reliance on provided business descriptions and AI insights for core business operations.
- Specific financial metrics beyond dividend yield are not available in the provided source data.